Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion

Behavioural Brain Research

Volumn 207, Issue 2, 2010, Pages 280-289

  Andó, Rómeó D ^a,b   Ádori, Csaba ^a   Kirilly, Eszter ^a   Molnár, Eszter ^a   Kovács, Gábor G ^c   Ferrington, Linda ^d   Kelly, Paul A T ^d   Bagdy, György ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anxiety; Functional imaging; LCMRglu; MDMA; Serotonin; Social interaction; SSRI antidepressant

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CITALOPRAM; FLUOXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE;

AGGRESSION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NERVE ENDING; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SOCIAL INTERACTION; THALAMUS VENTRAL NUCLEUS;

ANIMALS; ANXIETY; AXONS; BRAIN; CITALOPRAM; FLUOXETINE; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; RATS; SEROTONIN; SEROTONIN AGENTS; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; TIME FACTORS;

EID: 74449083688     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.10.011     Document Type: Article

References (35)

1. Ádori C., Ando R.D., Kovacs G.G., and Bagdy G. Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. The Journal of Comparative Neurology 497 2 (2006) 251-269
2. Ando R.D., Benko A., Ferrington L., Kirilly E., Kelly P.A., and Bagdy G. Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology 50 7 (2006) 884-896
3. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., and Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 4 4 (2001) 399-408
4. 3H]paroxetine-labeled serotonin uptake sites. The Journal of Pharmacology and Experimental Therapeutics 242 3 (1987) 911-916
5. Boothman L.J., and Sharp T. A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. Neuroreport 16 9 (2005) 891-896
6. Bull E.J., Hutson P.H., and Fone K.C. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity. Neuropharmacology 44 4 (2003) 439-448
7. Campbell B.M., and Merchant K.M. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Research 993 1-2 (2003) 1-9
8. Capela J.P., Carmo H., Remiao F., Bastos M.L., Meisel A., and Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Molecular Neurobiology 39 3 (2009) 210-271
9. Charney D.S., and Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Critical Reviews in Neurobiology 10 3-4 (1996) 419-446
10. Cook Jr. E.H., Metz J., Leventhal B.L., Lebovitz M., Nathan M., Semerdjian S.A., et al. Fluoxetine effects on cerebral glucose metabolism. Neuroreport 5 14 (1994) 1745-1748
11. Dekeyne A., Denorme B., Monneyron S., and Millan M.J. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology 39 6 (2000) 1114-1117
12. File S.E., and Hyde J.R. Can social interaction be used to measure anxiety?. British Journal of Pharmacology 62 1 (1978) 19-24
13. File S.E., Ouagazzal A.M., Gonzalez L.E., and Overstreet D.H. Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function. Pharmacology, Biochemistry, and Behavior 62 4 (1999) 695-701
14. Freo U., Ori C., Dam M., Merico A., and Pizzolato G. Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Research 854 1-2 (2000) 35-41
15. Green A.R., and McGregor I.S. On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology 162 4 (2002) 448-450
16. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacology & Therapeutics 65 3 (1995) 319-395
17. Haddjeri N., Szabo S.T., de Montigny C., and Blier P. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology 22 4 (2000) 346-356
18. Hajos M., Hajos-Korcsok E., and Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. British Journal of Pharmacology 126 8 (1999) 1741-1750
19. Harro J. Long-term partial 5-HT depletion: interference of anxiety and impulsivity?. Psychopharmacology 164 4 (2002) 433-434
20. Kantor S., Anheuer Z.E., and Bagdy G. High social anxiety and low aggression in Fawn-Hooded rats. Physiology & Behavior 71 5 (2000) 551-557
21. McBean D.E., Ritchie I.M., Olverman H.J., and Kelly P.A. Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. Brain Research 847 1 (1999) 80-84
22. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30 9 (2005) 1741-1750
23. Mechan A.O., Moran P.M., Elliott M., Young A.J., Joseph M.H., and Green R. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 159 2 (2002) 167-175
24. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., and McGregor I.S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). European Journal of Pharmacology 433 1 (2001) 91-99
25. O'Shea E., Orio L., Escobedo I., Sanchez V., Camarero J., Green A.R., et al. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. British Journal of Pharmacology 148 6 (2006) 778-785
26. Pineyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacological Reviews 51 3 (1999) 533-591
27. Qu Y., Chang L., Klaff J., Balbo A., and Rapoport S.I. Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (±)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology 28 2 (2003) 244-252
28. Quate L., McBean D.E., Ritchie I.M., Olverman H.J., and Kelly P.A. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. Psychopharmacology 173 3-4 (2004) 287-295
29. Sabol K.E., Lew R., Richards J.B., Vosmer G.L., and Seiden L.S. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. The Journal of Pharmacology and Experimental Therapeutics 2760 2 (1996) 846-854
30. Salchner P., and Singewald N. Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43 8 (2002) 1238-1248
31. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., and Ricaurte G.A. Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. The Journal of Pharmacology and Experimental Therapeutics 264 3 (1993) 1484-1491
32. Singewald N., Salchner P., and Sharp T. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biological Psychiatry 53 4 (2003) 275-283
33. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M.H., Patlak C.S., Pettigrew K.D., et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. Journal of Neurochemistry 28 5 (1977) 897-916
34. To C.T., Anheuer Z.E., and Bagdy G. Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 10 3 (1999) 553-555
35. To C.T., and Bagdy G. Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38 2 (1999) 279-282